How RxSight, Inc. stacks up

RXST · against 588 other Healthcare companies listed in US-listed

Valuation

33/ 100

Below the middle of the pack.

Ranked #254 of 589 · scores higher than 50% of peers

Bars: peers in each 10-point band of the valuation score

75 peers with a valuation score of 30–39, including RXST · Click a bar to see the companies

Why valuation scores 33?

Weighted metrics compared with all Healthcare companies.

Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -4.2% vs peer median 1.5%
Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -14.2% vs peer median 0.0%

Metric by metric

Position: dot = RXST, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	RXST	Peer median	Better than	Weight
Earnings yieldHigher is better · 577 reported	-24.8%	-4.3%	18%	30%
EBITDA yieldHigher is better · 578 reported	-30446.7%	-0.8%	0%	50%
Free cash flow yieldHigher is better · 553 reported	-14.2%	-2.3%	23%	20%
Book yieldHigher is better · 587 reported	138.0%	25.9%	95%	Context only

Ranking by valuation score

Top 5 and the companies ranked around RXST

Rank	Company	Market cap	Valuation	Overall
1	Clinuvel Pharmaceuticals LimitedCUVL · US-listed	256M USD	98	80
2	Arbutus Biopharma CorporationABUS · US-listed	595M USD	96	97
2	CorMedix Inc.CRMD · US-listed	433M USD	96	81
2	Community Health Systems, Inc.CYH · US-listed	289M USD	96	57
2	InMode Ltd.INMD · US-listed	810M USD	96	69
⋯
254	Palvella Therapeutics, Inc.PVLA · US-listed	2.2B USD	33	48
254	Rocket Pharmaceuticals, Inc.RCKT · US-listed	276M USD	33	46
254	Relmada Therapeutics, Inc.RLMD · US-listed	455M USD	33	53
254	Atrium Therapeutics, Inc.RNA · US-listed	149M USD	33
254	RxSight, Inc.RXST · US-listed	191M USD	33	38
254	Sionna Therapeutics, Inc.SION · US-listed	165M USD	33	50
254	SELLAS Life Sciences Group, Inc.SLS · US-listed	1.8B USD	33
254	Sutro Biopharma, Inc.STRO · US-listed	158M USD	33	14
254	Spyre Therapeutics, Inc.SYRE · US-listed	8.8B USD	33	50

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…